Population Pharmacokinetics of Dupilumab in Adults, Adolescents, and Children With Eosinophilic Esophagitis.

What was studied

This study looked at how the body handles the drug dupilumab. It focused on people with eosinophilic esophagitis. The team built a computer model of drug levels in the blood. They used data from 6 studies in healthy adults. They also used data from 3 trials in people with the disease. These trials took in adults, teens and children aged 1 and up.

What they found

Body weight changed how fast the drug left the body. Weight also changed how widely the drug spread through the body. In children and teens, weight changes during the study also mattered. The level of albumin in the blood also changed how fast the drug cleared. Age did not have a clear effect. Drug levels from trials lasting up to 52 weeks backed up the model. Computer tests pointed to other dose plans for some body weights. For 5 to under 15 kg, the plan was 200 mg every 3 weeks. For 40 to under 60 kg, the plan was 300 mg weekly. These plans gave drug levels closer to 300 mg weekly in an earlier trial.

What it means for patients

The authors say the model helped guide drug approval by health agencies. They say it may also help plan future trials. Their work suggests that dose plans based on body weight can change drug levels.

Why it is not certain yet

This study used a model to study drug levels in the blood. It did not test how well each dose plan works. The new dose plans came from computer tests. The abstract does not say these plans were tried in patients. The abstract also gives no results on symptoms or harms.

Source

Population Pharmacokinetics of Dupilumab in Adults, Adolescents, and Children With Eosinophilic Esophagitis.

We restate facts from the source record in our own words. The original wording belongs to its publisher.